A Randomized study to evaluate the safety, efficacy and pharmacokinetics of three dose levels (60, 75 and 100 mg/m2) of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension in women with Metastatic Breast Cancer

Trial Profile

A Randomized study to evaluate the safety, efficacy and pharmacokinetics of three dose levels (60, 75 and 100 mg/m2) of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension in women with Metastatic Breast Cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 New trial record
    • 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top